Key result
Eprosartan administration in patients with hepatic disease resulted in a ~40% higher total AUC compared to healthy subjects (PE 1.42; 90% CI 0.94-2.14).
Why the study?
Does hepatic disease alter the pharmacokinetics and plasma protein binding of a single 100 mg oral dose of eprosartan?
Population
16 subjects (8 healthy subjects with normal hepatic function and 8 patients with hepatic disease)
Comparison
Single oral dose of eprosartan 100 mg vs Healthy subjects with normal hepatic function…
Design
Other
Authors
Loading...
May increase exposure in hepatic impairment; leaves open need for confirmatory PK studies.
Does hepatic disease alter the pharmacokinetics and plasma protein binding of a single 100 mg oral dose of eprosartan?
Effect estimate: PE 1.42 (95% CI 0.94-2.14)
Hepatic disease increases eprosartan exposure by approximately 40%, indicating that dosing should be individualized in this population.
Tenero et al. (1998) studied Hepatic disease (n=16). Eprosartan vs. Healthy subjects with normal hepatic function was evaluated on Total area under the plasma concentration-time curve (AUC0-t) (PE 1.42, 95% CI 0.94-2.14). Eprosartan administration in patients with hepatic disease resulted in a ~40% higher total AUC compared to healthy subjects (PE 1.42; 90% CI 0.94-2.14).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: